WILMINGTON, Delaware, Feb. 21 -- AstraZeneca, a biopharmaceutical company, issued the following news release: * * * CALQUENCE(R) plus venetoclax approved in the US as first all-oral, fixed-duration combination for patients with chronic lymphocytic leukemia in the 1st-line setting CALQUENCE plus venetoclax demonstrated statistically significant and clinically meaningful improvement in progression-free survival vs. chemoimmunotherapy, with 77% of patients progression free at three years in AM more PR